Caris Life Sciences (NASDAQ:CAI) Lowered to “Hold” Rating by Wall Street Zen

Posted by on Dec 6th, 2025

Caris Life Sciences (NASDAQ:CAI – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Caris Life Sciences Trading Up 1.9%

CAI opened at $28.86 on Friday.

Caris Life Sciences Company Profile

(Get Free Report)

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.

Featured Stories

Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.